Plain-English translation of NCT06598202 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called small extracellular vesicles derived from human umbilical cord blood mesenchymal stem cells, given as nasal drops, to see if it can help people with ALS (amyotrophic lateral sclerosis). The medication contains tiny natural particles that researchers hope might protect nerve cells and reduce the progression of this serious disease. Half of the participants will receive the active treatment, and half will receive a placebo (a fake nasal drop that looks the same) so researchers can accurately measure whether the medication works.
ALS is a progressive disease where nerve cells gradually die, leading to weakness and paralysis. Current treatments like riluzole and edaravone can slow the disease only slightly, so there is an urgent need for new approaches that might offer greater benefit. This medication is being tested because early research suggests that stem cell-derived particles may help protect nerve cells and reduce inflammation in the brain and spinal cord.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive nasal drops (either the active medication or placebo) once daily, twice per week, for two weeks total. The study has two phases: the first phase tests different doses to find the safest level, and the second phase tests whether the medication helps compared to placebo. You will need to visit the hospital for assessments and monitoring to make sure the treatment is safe and to measure any changes in your ALS symptoms.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
China